Intimation of allotment of equity shares.

Novelix Pharmaceuticals has allotted 28,10,000 equity shares of Rs. 10 face value each at Rs. 20 per share (including Rs. 10 premium) to 14 investors. These shares were issued upon conversion of an equal number of warrants that were originally allotted on 10 January 2025 via a preferential issue. The warrant holders (promoter and non-promoter groups) had paid Rs. 15 per warrant upfront (75% of issue price) and paid the remaining Rs. 5 per warrant at the time of conversion. The company received Rs. 4.21 crore upon conversion. Post-allotment, the company's paid-up equity capital has increased from Rs. 21.08 crore (21,085,000 shares) to Rs. 23.89 crore (23,895,000 shares). The allottees include promoter group entities such as Srinidhi Fine-Chemicals LLP and Narahari Belide, along with 11 non-promoter strategic investors.